Protocol Ledger

NCT05918094 · Phase III · RECRUITING

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

Interventional Phase III clinical trial protocol NCT05918094 sponsored by Sun Yat-sen University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-30 Enrollment: 540 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05918094
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)540 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05918094
Protocol FieldVerified Registry Value
NCT IdentifierNCT05918094
Consolidated Lead SponsorSun Yat-sen University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment540 participants (ESTIMATED)
Registered Start Date2023-04-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI